Interaction Between White Potato Consumption and Meal Timing on Glycemic Response and Appetite in Adults

November 13, 2025 updated by: Nick Bellissimo, PhD, Toronto Metropolitan University

Interaction Between White Potato Consumption and Meal Timing on Glycemic Response, Subjective Appetite, and Energy Intake in Adults.

The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A randomized within-subject repeated measures experiment will be used to study the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. In Experiment 1, participants will consume, in a random order on separate mornings, one of six test meals consisting of an egg omelette and a test side of: (1) Oven-baked home fries, (2) Oven-baked white russet potatoes, (3) Deep-fried, quick serve fries, (4) Oven-baked fries, (5) Oven-baked cauliflower tots, or (6) no side. Acute glycemic response and subjective appetite will be measured at baseline and over 120-mins post treatment consumption. At 120-min, food intake will be evaluated via an ad libitum lunch. Rest of day food intake and glycemic response will be collected until the participant goes to bed. Blood glucose measurements will be collected using the Dexcom G7 continuous glucose monitoring system.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M5B2K3
        • Recruiting
        • Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18 - 65 years
  • within the healthy body weight range [body mass index (BMI) between 18.5 - 24.9 kg/m2].

Exclusion Criteria:

  • have a previous diagnosis of diabetes and gastrointestinal, liver or kidney disease;
  • have had a major medical or surgical event within the past 6 months;
  • have had any significant weight fluctuation in the past 6-months;
  • are taking medication that may influence dependent measures;
  • are or have been on a diet within the past 6 months;
  • skip breakfast or are unable to consume test treatment food.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Oven-baked Home Fries
Test Treatment
Other: Oven-baked Home Fries
Oven-baked Home Fries (241 g; McCain Ltd.). Test treatments matched for calories (284 kcal)
Experimental: Oven-baked White Russet Potato
Test Treatment
Other: Oven-baked White Russet Potato
Oven-baked White Russet Potato (299 g). Test treatments matched for calories (284 kcal)
Experimental: Oven-baked Fries
Test Treatment
Other: Oven-baked Fries
Oven-baked Fries (201 g; McCain Ltd.). Test treatments matched for calories (284 kcal)
Experimental: Deep Fried, Quick Serve Fries
Test Treatment
Other: Deep Fried, Quick Serve Fries
Deep Fried, Quick Serve Fries (108 g; McCain Ltd.). Test treatments matched for calories (284 kcal)
Experimental: Oven-baked Cauliflower Veggie Tots
Test Treatment
Other: Oven-baked Cauliflower Veggie Tots
Oven-baked Cauliflower Veggie Tots (186 g; Green Giant). Test treatments matched for calories (284 kcal)
Experimental: No Side
Test Treatment
Other: No Side
No side control (no caloric contribution).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Glycemic Response (Acute Phase)
Time Frame: Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
Blood glucose (mmol/L). Blood glucose concentrations will be measured using a Dexcom G7 CGM system.
Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
Rest-of-day Blood Glucose
Time Frame: Continuous measurements for 24 hours post-treatment consumption.
Blood glucose (mmol/L). Rest-of-day blood glucose concentrations will be determined using a Dexcom G7 CGM system.
Continuous measurements for 24 hours post-treatment consumption.
Ad Libitum Food Intake
Time Frame: At 120 minutes post-treatment consumption
Lunch pizza meal. Food intake will be determined by weighing the meal before and after serving. The net weight of the test meal will be converted to calories.
At 120 minutes post-treatment consumption

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Subjective Appetite
Time Frame: Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
A visual analogue scale (VAS) with four questions will be administered to assess desire to eat, fullness, hunger, and prospective food consumption. Individual questions will be used to form a composite score. Each VAS will be administered via a digital software application (Express VAS, Toronto, Ontario, Canada) on a Dell tablet where participants will place an 'X" on the VAS line (100 unit scale).
Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
Rest-of-day Food Intake
Time Frame: For the rest of the day following test session completion (1 day)
Participants will be sent home with a rest-of-the-day food intake recall sheet to record their snacks, meals, and beverages. Rest of day food log.
For the rest of the day following test session completion (1 day)
Subjective Emotions
Time Frame: Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).
A visual analogue scale (VAS) with thirteen questions will be administered to assess subjective emotions and mood (aggression, anger, excitement, disappointment, happiness, upset, frustration, alertness, sadness, tension, exhaustion, calmness, and sleepiness). Individual questions will be used to form a composite emotion score. Each VAS will be administered via a digital software application (Express VAS, Toronto, Ontario, Canada) on a Dell tablet where participants will place an 'X" on the VAS line (100 unit scale).
Change from baseline (measured at baseline (0-minute), 15-minute, 30-minute, 60-minute, 90-minute, and 120-minute post-treatment consumption).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Toronto Metropolitan University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Alliance for Potato Research and Education

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 30, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 13, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 13, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 17, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 17, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 13, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REB: 25-172 [A]

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings